Asia Tracks
ADC antibody-drug conjugates
Antibody-drug conjugates: chemotherapy attached to an antibody and delivered straight into cancer cells.
40 assets
Daiichi Sankyo · Enhertu (DS-8201) · Approved
CAR-T and cell therapy
Cell therapy: turning a patient's or donor's immune cells into a living drug.
25 assets
CARsgen Therapeutics Holdings Limited · Satricabtagene autoleucel (satri-cel / CT041) · Approved
GLP-1
GLP-1 and obesity drugs: mimicking a gut hormone to curb appetite and control blood sugar.
26 assets
Chugai Pharmaceutical · orforglipron · Approved
HDAC inhibitors
HDAC inhibitors: adjusting gene switches to change how cancer and immune cells behave.
11 assets
Chipscreen Biosciences · Tucidinostat / chidamide / Epidaza · Approved
PD-1/VEGF
PD-1/VEGF bispecifics: one molecule that releases the immune brake and cuts off tumour blood supply.
32 assets
Akeso · cadonilimab · Approved
Oligonucleotide drugs
Oligonucleotide drugs: short strands of RNA that switch off a disease gene's message.
15 assets
Nippon Shinyaku Co., Ltd. / National Center of Neurology and Psychiatry · NS-065/NCNP-01 viltolarsen · Approved
T-cell engagers
T-cell engagers: bispecific or trispecific antibodies that bridge cancer cells and T cells.
16 assets
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · GR1803 (velinotamig / CLN-803) · Phase 3